Advertisement

Search Results

Advertisement



Your search for ASCO Post matches 12881 pages

Showing 201 - 250


bladder cancer
immunotherapy

FDA ODAC Votes in Favor of Retaining Accelerated Approval for Bladder Cancer Treatments

Roche has announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining the accelerated approval of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for...

breast cancer
legislation
health-care policy

Breast Reconstruction Disparities Improved With Medicaid Expansion

Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction among non-Hispanic Black women, achieving parity at times with non-Hispanic White women, according to a new study presented by Sharon Lum, MD, and colleagues at the American Society...

breast cancer
survivorship

Low-Risk Breast Cancer Survivors May Experience Long-Term Physical and Psychological Effects

Survivors of low-risk breast cancer may experience wide-ranging and significant physical and psychological symptoms after cancer treatment, according to a new study presented by Jessica Schumacher, PhD, and colleagues at the American Society of Breast Surgeons (ASBrS) Annual Meeting. Researchers...

breast cancer

Cryoablation Emerging as Effective Treatment for Low-Risk Breast Cancers

Nonsurgical breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, is proving to be an effective alternative to surgery for small breast tumors with low-risk features in women older than age 60. These were the early findings from 3-year results of the...

breast cancer
covid-19

COVID-19 Pandemic Drove Strategic New Breast Cancer Approaches to Avoid Hospitalization

The COVID-19 pandemic rapidly altered breast cancer treatment approaches, with a significant rise in neoadjuvant endocrine therapy for estrogen receptor–positive tumors, enabling immediate evidence-based treatment of women with an extremely common form of breast cancer, while delaying surgery and...

Updated Information on Sotorasib Dose-Comparison Study

Amgen has announced that it agreed with the U.S. Food and Drug Administration's proposed postmarketing requirement to conduct, as part of the ongoing development program, a multicenter randomized clinical trial to compare the safety and efficacy of sotorasib at 960 mg once daily vs a lower daily...

hematologic malignancies
immunotherapy

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on CAR T Cells for Hematologic Malignancies: Where We’re At

issues in oncology
bladder cancer
prostate cancer

YouTube Videos on Bladder Cancer: Study Focuses on Quality of Content

Social media platforms are valuable tools for educating patients about serious health topics, but they can also spread false and biased information with potentially harmful results, according to recent research published by Stacy Loeb, MD, MSc, and colleagues in European Urology. Researchers...

issues in oncology
head and neck cancer

New Research Finds Few Young Adult Men Have Received the HPV Vaccine

Using data from the 2010–2018 National Health Interview Surveys, Chen et al found that just 16% of men who were 18 to 21 years old had received at least one dose of the human papillomavirus (HPV) vaccine at any age. In comparison, 42% of women in the same age bracket had gotten at least one shot of ...

breast cancer
immunotherapy

FDA ODAC Votes in Favor of Maintaining Accelerated Approval of Atezolizumab/Nab-paclitaxel for PD-L1–Positive, Metastatic Triple-Negative Breast Cancer

Roche announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted seven to two in favor of maintaining accelerated approval of atezolizumab in combination with chemotherapy (nanoparticle albumin-bound paclitaxel, or nab-paclitaxel) for the treatment of ...

multiple myeloma

Paul G. Richardson, MD, and Peter M. Voorhees, MD, on Multiple Myeloma: Surveying the Evolving Landscape of Up-Front Drugs

global cancer care
issues in oncology

Chernobyl at 35 Years: An Oncologist’s Perspective

Editor’s note: Dr. Gale is an authority on medical response to nuclear and radiation accidents and participated in rescue efforts at the Chernobyl disaster, as well as at Goiania, Tokaimura, and Fukushima, among other radiation and nuclear accidents. Anyone reading the popular press or even...

lymphoma
immunotherapy

FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma

On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, ...

AACR and The Mark Foundation for Cancer Research Announce New Grants

The American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research recently announced five grants to support innovative research focused on understanding the influence of a patient’s biology on the genesis, development, treatment, and survivorship of cancer. Each...

AMA Salutes End to Ban on Transgender Americans in the Military

On January 25, 2021, Susan R. Bailey, MD, President of the American Medical Association (AMA), issued the following statement: “The AMA welcomes the President’s decision to reverse the policy that largely barred transgender people from serving in the military, because there is no medically valid...

NCI Statement on Ending Structural Racism in Biomedical Research

On March 2, 2021, the National Cancer Institute (NCI) issued the following statement: As one of the 27 institutes and centers that make up the NIH [National Institutes of Health], the National Cancer Institute stands with [NIH Director] Dr. Francis Collins and the entire NIH in supporting UNITE. “I ...

Turning Confusion Into Clarity: Lessons Learned From Autism Spectrum Disorder

Autism spectrum disorder refers to a group of conditions characterized by difficulty in navigating normal social situations and having all-absorbing repetitive behaviors or stereotyped interests. At the milder end of the spectrum is Asperger’s syndrome, generally confined to people with higher...

Kathy Giusti, MBA; Nancy Pelosi; and Charles L. Sawyers, MD, FAACR, to Receive AACR Distinguished Public Service Awards

The American Association for Cancer Research (AACR) will present Distinguished Public Service Awards to three individuals whose extraordinary work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, advocacy,...

integrative oncology
cost of care

Clinician Recommendations May Pique Patients’ Interest in Complementary and Integrative Therapies

Patients with cancer expressed more interest in complementary and integrative medicine services when these services were recommended by an oncologist or other medical professional or were provided for free in a clinical trial, according to a survey reported in JCO Oncology Practice.1 The survey...

integrative oncology
cost of care

How Interested Are Patients in Integrative Therapies, and How Much Are They Willing to Pay for Them?

The top two barriers to accessing complementary and integrative therapies, according to a survey of 576 patients with cancer and caregivers, were cost, cited by 56%, and a lack of knowledge about the therapies, cited by 52.1%. “Other barriers included a lack of time (29.2%), location of the...

breast cancer

Grateful to Be Alive

Everything about my breast cancer diagnosis, from my presentation to diagnosis, was strange. In the spring of 2006, I was performing my monthly breast self-exam when I felt a hard lump in the upper left quadrant of my left breast. Having lost a good friend to breast cancer 4 years earlier, I was...

IMF Launches Initiative to Improve Outcomes in Multiple Myeloma Among Black Americans

The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. The IMF is working with Atrium Health Levine Cancer Institute’s Disparities &...

issues in oncology

Ethical Considerations Before Launching a Clinical Cancer Trial

Randomized clinical trials are highly regulated initiatives that must comply with multiple requirements while maintaining high epistemic standards, a balance that becomes increasingly difficult as the research questions surrounding immunotherapy and targeted agents become more complex. To shed...

A Physician-Scientist’s Mother, Who Nursed Those With Chronic Diseases, Fueled His Passion for Biomedical Research

For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Griffin P. Rodgers, MD, MACP, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Dr. Rodgers, a physician-scientist,...

Narjust Duma, MD, Appointed to Dual Role at Dana-Farber Cancer Institute/Harvard Medical School

Narjust Duma, MD, was recently named Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine at Dana-Farber Cancer Institute/Harvard Medical School. In her role at the Cancer Care Equity Program, Dr. Duma will develop strategies to diminish health-care disparities...

Brendon Stiles, MD, Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein

Leading cardiothoracic surgeon and researcher Brendon Stiles, MD, has been appointed Chief of the Division of Thoracic Surgery & Surgical Oncology in the Department of Cardiothoracic and Vascular Surgery at Montefiore Health System and Albert Einstein College of Medicine. Dr. Stiles will also...

CancerCare® Appoints Mark D. Peters II, PharmD, as Vice President for New Business Development and Outreach

CancerCare, the leading national nonprofit organization providing free support services to anyone affected by cancer, recently welcomed Mark D. Peters II, PharmD, to its team as Vice President for New Business Development and Outreach. Dr. Peters, who has more than 30 years of clinical and...

Neeraj Agarwal, MD, Named Senior Director of Clinical Research Innovation by Huntsman Cancer Institute

Huntsman Cancer Institute (HCI) at the University of Utah (U of U) announced the appointment of Neeraj Agarwal, MD, physician-scientist at HCI and Professor of Internal Medicine at the U of U, as Senior Director of Clinical Research Innovation. In this role, Dr. Agarwal will oversee critical...

gynecologic cancers

Can Brachytherapy for Cervical Cancer Continue After Uterine Perforation?

A study published by Small et al in the journal Brachytherapy found that the common procedure of interstitial or intracavitary radiotherapy may continue safely—potentially without delay or antibiotics—in patients with cervical cancer following uterine perforation. According to the World Health...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

FDA Pipeline: Bemarituzumab Granted Breakthrough Therapy Designation for FGFR2b-Overexpressing, HER2-Negative Gastric Cancer

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b)-overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma...

lung cancer

Nivolumab/Ipilimumab Plus Two Cycles of Histology-Based Chemotherapy: Another Option in First-Line Metastatic NSCLC

Introduction of immunotherapy has revealed a paradigm shift in the management of patients with metastatic non–small cell lung cancer (NSCLC) that does not harbor a therapeutically targetable driver mutation. Over the past 5 years, several trials have informed treatment decisions, based on disease...

gynecologic cancers
immunotherapy

FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer

On April 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior...

health-care policy

NCCN 2021 Virtual Annual Conference

New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling human papillomavirus (HPV)-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021...

Expert Point of View: Lisa Baumann Kreuziger, MD, MS

Lisa Baumann Kreuziger, MD, MS, Associate Professor of Hematology/Oncology at Versiti/Medical College of Wisconsin, Milwaukee, introduced Terry B. Gernsheimer, MD, at the Plenary Session and spoke with The ASCO Post about the results of the study. “The investigators of the A-TREAT trial tested a...

colorectal cancer
genomics/genetics

Study Explores Rates of Germline Mutations in Patients With Colorectal Cancer

In a recent study published by Uson Junior et al in Clinical Gastroenterology and Hepatology, researchers found one in six patients with colorectal cancer had an inherited cancer-related genetic mutation, which may be linked to a predisposition to the disease. In addition, the researchers...

kidney cancer
bladder cancer
prostate cancer
immunotherapy

Genitourinary Oncology Highlights 2020–2021 Almanac

Landmark changes in the treatment of genitourinary cancers have occurred over the past year, as summarized in this year’s Genitourinary Oncology Almanac from The ASCO Post. Starting with our area of focus, metastatic renal cell carcinoma, the saga continues with two more positive phase III trials...

immunotherapy

Immune Checkpoint Inhibitors and Cutaneous Toxicity: Population-Level Analysis

Immune checkpoint inhibitors have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a...

leukemia

Acute Myeloid Leukemia World Awareness Day 2021: April 21

After a great response to Acute Myeloid Leukemia World Awareness Day (AML WAD) in 2020, Know AML looks forward to commemorating AML WAD in 2021. AML WAD will take place on April 21, 2021, with the aim to facilitate and improve knowledge of AML worldwide through collaborative participation. Know AML ...

issues in oncology

To Advance Health Equity, Put Real-World Cancer Data to Work

Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons—like institutional racism and poverty—are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health...

bladder cancer
gynecologic cancers
hepatobiliary cancer
solid tumors
colorectal cancer
immunotherapy

FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More

Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for urothelial cancer, cervical cancer, cholangiocarcinoma, solid tumors, and colorectal cancer. Acceptance of Two Supplemental Biologics License Applications for Enfortumab Vedotin-ejfv in...

breast cancer
survivorship

Overweight Breast Cancer Survivors May Be at Increased Risk of Developing a Secondary Malignancy

Breast cancer survivors who are overweight have a statistically significant increased risk of developing second primary cancers, according to results from a study conducted by Feigelson et al and published in the Journal of the National Cancer Institute. “These findings have important public health ...

leukemia
multiple myeloma
covid-19

Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma

Two new studies published in the journal Blood suggest that the BNT162b2 mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma. According to researchers, these studies could help inform the ideal time for vaccination of these...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma

Today, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. CheckMate 649 The efficacy of the...

skin cancer
immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Nivolumab Plus Ipilimumab vs Nivolumab Alone

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, University of Sydney, discusses results of the CheckMate 915 trial, which may reinforce nivolumab as an adjuvant standard of care in patients with stage IIIB–D/IV melanoma, with or without complete lymphadenectomy (Abstract CT004).

hepatobiliary cancer

Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib

Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements...

immunotherapy

Michel Sadelain, MD, PhD, on the Road to Synthetic Immunity: Novel CAR Designs

Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the challenges in developing CAR T-cell therapy, as well as the progress being made, such as creating hybrid CAR and T-cell receptors that should enable T cells to recognize much lower levels of antigens. The field, he...

issues in oncology

Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer

Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response ...

cost of care
survivorship

Adult Survivors of AYA Cancers May Be More Likely to Experience Medical Financial Hardship

A new study has found higher rates of medical financial hardship among adult survivors of adolescent and young adult (AYA) cancers than in adults without a history of cancer in the United States. The research was published by Lu et al in JNCI: The Journal of the National Cancer Institute....

issues in oncology

Ralph R. Weichselbaum, MD, on Oligometastasis: Biologic Basis and Therapeutic Opportunities

Ralph R. Weichselbaum, MD, of the University of Chicago, discusses oligometastasis as a part of the metastatic spectrum where ablative therapies, such as surgery or stereotactic body radiotherapy, may be curative alone or with systemic agents, as well as some potential biomarkers to guide treatment ...

immunotherapy
issues in oncology

Charlotte E. Ariyan, MD, PhD, on Metastasectomy After Immunotherapy: Is It Effective?

Charlotte E. Ariyan, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses improved outcomes with metastasectomy in the setting of checkpoint inhibitors, with the removal of residual disease and “escape” lesions. Surgical outcomes may also be better than targeted treatments, although...

Advertisement

Advertisement



Advertisement